ONC — Oncolytics Biotech Share News
0.000.00%
Last trade - 00:00- CA$138.32m
- CA$123.56m
Brief: Oncolytics Biotech Presents Positive Interim Safety Update from Phase 2 Triple-Negative Breast Cancer Trial at the 2021 San Antonio Breast Cancer Symposium
Brief: Oncolytics Biotech Inc Says As Of September 30, 2021, Co Reported $48.1 Mln In Cash And Cash Equivalents
Brief: Oncolytics Biotech Reports 2021 Third Quarter Development Highlights And Financial Results
Brief: Oncolytics Biotech Doses First Patient In Phase 1/2 Study Of Gastrointestinal Cancers Therapies
Brief: Oncolytics Biotech Partner Adlai Nortye Doses First Patient In Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel
Oncolytics gains as cancer treatment shows promise in mice
Brief: Oncolytics Biotech Posts Q2 Loss Per Share C$0.13
Brief: Oncolytics Biotech Reports 2021 First Quarter Financial Results
Brief: Oncolytics Biotech® Presents Preclinical Data On Pelareorep-Based Combination Therapies At AACR Annual Meeting
Brief: Oncolytics Biotech® And Solti Achieve Primary Endpoint In Aware-1 Study
Brief: Oncolytics Biotech Reports Q4 Loss Per Share C$0.21
Brief: Oncolytics Biotech Establishes New At-The-Market Facility
Brief: Oncolytics Biotech Reports Preclinical Data Demonstrating Synergistic Anti-Cancer Activity Of Pelareorep Combined With Car T Cell Therapy In Solid Tumors
Brief: Oncolytics Biotech Inc Announces Positive Clinical Results Against Glioblastoma Multiforme
Brief: Oncolytics Biotech Reports Q3 Loss Per Share C$0.16
Oncolytics Biotech: Up on collaboration with Roche in cancer study
Brief: Oncolytics Biotech Collaborates With Roche And Aio For Gastrointestinal Cancer Trial
Brief: Oncolytics Doses First Patient In Phase 2 IRENE Study Evaluating Pelareorep-Anti-PD-1 Combination Treatment
Brief: Oncolytics Biotech® Reports 2020 Second Quarter Financial Results And Operational Highlights